Department of Public Health, University of Kisangani, Kisangani, Democratic Republic of Congo (DRC).
National Institute for Biomedical Research, Kinshasa, DRC.
PLoS One. 2023 Oct 17;18(10):e0293077. doi: 10.1371/journal.pone.0293077. eCollection 2023.
No distinctive clinical signs of Ebola virus disease (EVD) have prompted the development of rapid screening tools or called for a new approach to screening suspected Ebola cases. New screening approaches require evidence of clinical benefit and economic efficiency. As of now, no evidence or defined algorithm exists.
To evaluate, from a healthcare perspective, the efficiency of incorporating Ebola prediction scores and rapid diagnostic tests into the EVD screening algorithm during an outbreak.
We collected data on rapid diagnostic tests (RDTs) and prediction scores' accuracy measurements, e.g., sensitivity and specificity, and the cost of case management and RDT screening in EVD suspect cases. The overall cost of healthcare services (PPE, procedure time, and standard-of-care (SOC) costs) per suspected patient and diagnostic confirmation of EVD were calculated. We also collected the EVD prevalence among suspects from the literature. We created an analytical decision model to assess the efficiency of eight screening strategies: 1) Screening suspect cases with the WHO case definition for Ebola suspects, 2) Screening suspect cases with the ECPS at -3 points of cut-off, 3) Screening suspect cases with the ECPS as a joint test, 4) Screening suspect cases with the ECPS as a conditional test, 5) Screening suspect cases with the WHO case definition, then QuickNavi™-Ebola RDT, 6) Screening suspect cases with the ECPS at -3 points of cut-off and QuickNavi™-Ebola RDT, 7) Screening suspect cases with the ECPS as a conditional test and QuickNavi™-Ebola RDT, and 8) Screening suspect cases with the ECPS as a joint test and QuickNavi™-Ebola RDT. We performed a cost-effectiveness analysis to identify an algorithm that minimizes the cost per patient correctly classified. We performed a one-way and probabilistic sensitivity analysis to test the robustness of our findings.
Our analysis found dual ECPS as a conditional test with the QuickNavi™-Ebola RDT algorithm to be the most cost-effective screening algorithm for EVD, with an effectiveness of 0.86. The cost-effectiveness ratio was 106.7 USD per patient correctly classified. The following algorithms, the ECPS as a conditional test with an effectiveness of 0.80 and an efficiency of 111.5 USD per patient correctly classified and the ECPS as a joint test with the QuickNavi™-Ebola RDT algorithm with an effectiveness of 0.81 and a cost-effectiveness ratio of 131.5 USD per patient correctly classified. These findings were sensitive to variations in the prevalence of EVD in suspected population and the sensitivity of the QuickNavi™-Ebola RDT.
Findings from this study showed that prediction scores and RDT could improve Ebola screening. The use of the ECPS as a conditional test algorithm and the dual ECPS as a conditional test and then the QuickNavi™-Ebola RDT algorithm are the best screening choices because they are more efficient and lower the number of confirmation tests and overall care costs during an EBOV epidemic.
埃博拉病毒病(EVD)没有明显的临床特征,这促使人们开发快速筛查工具或寻求新的方法来筛查疑似埃博拉病例。新的筛查方法需要有临床获益和经济效率的证据。到目前为止,还没有证据或确定的算法存在。
从医疗保健的角度评估在疫情爆发期间将埃博拉预测评分和快速诊断检测纳入 EVD 筛查算法的效率。
我们收集了有关快速诊断检测(RDT)和预测评分准确性测量的信息,例如灵敏度和特异性,以及对疑似病例进行病例管理和 RDT 筛查的成本。计算了每位疑似患者的医疗保健服务总成本(个人防护设备、程序时间和标准护理(SOC)成本)和 EVD 的确诊情况。我们还从文献中收集了疑似患者中的 EVD 患病率。我们创建了一个分析决策模型来评估八种筛查策略的效率:1)使用世界卫生组织(WHO)的 Ebola 疑似病例定义筛查疑似病例,2)使用 ECPS 在 -3 分的截止值筛查疑似病例,3)使用 ECPS 作为联合检测筛查疑似病例,4)使用 ECPS 作为条件检测筛查疑似病例,5)使用世界卫生组织(WHO)的 Ebola 疑似病例定义,然后使用 QuickNavi™-Ebola RDT 筛查疑似病例,6)使用 ECPS 在 -3 分的截止值和 QuickNavi™-Ebola RDT 筛查疑似病例,7)使用 ECPS 作为条件检测和 QuickNavi™-Ebola RDT 筛查疑似病例,以及 8)使用 ECPS 作为联合检测和 QuickNavi™-Ebola RDT 筛查疑似病例。我们进行了成本效益分析,以确定一种能使每位正确分类的患者的成本最小化的算法。我们进行了单因素和概率敏感性分析,以测试我们发现的稳健性。
我们的分析发现,双重 ECPS 作为条件检测与 QuickNavi™-Ebola RDT 算法是 EVD 最具成本效益的筛查算法,有效性为 0.86。成本效益比为每例正确分类的患者 106.7 美元。以下算法的成本效益比也较低,包括 ECPS 作为条件检测的有效性为 0.80,效率为 111.5 美元/例,以及 ECPS 作为联合检测与 QuickNavi™-Ebola RDT 算法的有效性为 0.81,成本效益比为每例正确分类的患者 131.5 美元。这些发现对疑似人群中 EVD 的流行率和 QuickNavi™-Ebola RDT 的灵敏度的变化敏感。
本研究结果表明,预测评分和 RDT 可以提高埃博拉病毒的筛查效果。使用 ECPS 作为条件检测算法和双重 ECPS 作为条件检测,然后是 QuickNavi™-Ebola RDT 算法是最佳的筛查选择,因为它们效率更高,并且可以减少确认检测的数量和整个疫情期间的护理成本。